From EV production
to new applications.

Source cells. Optimized production.

EV production from sources including human iPSCs and MSCs.

GeneFront has optimized its production processes and developed proprietary culture media to increase EV production capacity. Source-cell selection, production needs, and characterization requirements begin with the intended research application. Our development capabilities include 3D human iPSC culture and scalable MSC expansion and EV-collection workflows.

EVs engineered for the question.

Engineering EVs for biomolecule delivery research.

Our work explores how EV engineering can support delivery of selected biomolecules to different organs. Discuss your cargo, target organ, and research objectives with our team.

Delivery over time.

GeneFront-developed sustained-release EV formulations (SReEV).

These formulations support research into longer-term delivery of biomolecules and organ-targeted applications. The development portfolio includes topical, hydrogel, matrix, and lyophilized approaches. Discuss formulation fit, release behavior, stability, and supporting evidence for your project.

Formulation formats under development

• Hydrogel and matrix-based EV formulations.
• Lyophilized formats for reconstitution and stability research.
• Encapsulation approaches for cargo protection and delivery research.
• Topical serum, hydrogel-mask, and gel concepts for cosmetic formulation research.

These are development areas; project-specific status and intended use are confirmed with our team.

Investigate the molecular signal.

EVHook is one research platform within the GeneFront portfolio.

Cell-specific EV capture plates help researchers investigate selected EV populations and their molecular cargo, including in biomarker discovery and disease-related research.